- Home
- AVPT vs RCKT Comparison
AVPT vs RCKT Comparison
Compare AVPT & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVPT | RCKT |
|---|---|---|
| Founded | 2001 | 1999 |
| Country | United States | United States |
| Employees | 2934 | 202 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 534.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | AVPT | RCKT |
|---|---|---|
| Price | $9.99 | $3.47 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 14 |
| Target Price | $16.64 | ★ $29.73 |
| AVG Volume (30 Days) | 1.4M | ★ 4.1M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.00 | N/A |
| Revenue Next Year | $19.63 | $51.17 |
| P/E Ratio | $1,348.94 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.24 | $2.19 |
| 52 Week High | $20.25 | $8.26 |
Technical Indicators
Market Signals| Indicator | AVPT | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 45.11 | 37.67 |
| Support Level | $9.86 | $3.43 |
| Resistance Level | $11.42 | $3.52 |
| Average True Range (ATR) | 0.35 | 0.36 |
| MACD | 0.04 | -0.14 |
| Stochastic Oscillator | 54.94 | 6.69 |
Price Performance
Historical ComparisonAbout AVPT AvePoint Inc.
AvePoint Inc provides customizable solutions to optimize SaaS operations, enable secure collaboration, and accelerate digital transformation across technologies and industries. Its Confidence Platform delivers a comprehensive set of cloud-based solutions enabling IT operations, development operations, and cybersecurity professionals to monitor and secure the digital workplace using SaaS tools.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.